Carl Merton Purchases 10,000 Shares of Tilray Brands (NASDAQ:TLRY) Stock

Tilray Brands, Inc. (NASDAQ:TLRY) CFO Carl Merton bought 10,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were acquired at an average cost of $4.62 per share, for a total transaction of $46,200.00. Following the completion of the transaction, the chief financial officer owned 139,753 shares of the company’s stock, valued at approximately $645,658.86. The trade was a 7.71% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tilray Brands Price Performance

Shares of TLRY stock opened at $4.43 on Thursday. The firm has a fifty day moving average of $4.62 and a two-hundred day moving average of $6.13. The firm has a market cap of $516.32 million, a P/E ratio of -4.10 and a beta of 1.90. Tilray Brands, Inc. has a 1-year low of $3.67 and a 1-year high of $23.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.21 and a quick ratio of 1.37.

Tilray Brands (NASDAQ:TLRY) last issued its earnings results on Tuesday, July 28th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.42). Tilray Brands had a negative net margin of 13.11% and a negative return on equity of 7.76%. The company had revenue of $281.71 million during the quarter, compared to analyst estimates of $246.30 million. As a group, research analysts anticipate that Tilray Brands, Inc. will post -0.4 earnings per share for the current fiscal year.

Key Stories Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: CFO Carl Merton purchased 10,000 Tilray shares for approximately $46,200, increasing his direct ownership by 7.71%. The transaction may signal that management believes the stock is undervalued. SEC insider purchase filing
• Positive Sentiment: Director Denise Faltischek purchased 2,500 shares at an average price of $4.78, adding roughly $11,950 to her position. The second insider purchase in the recent news flow provides additional, though relatively modest, support for the shares. Denise Faltischek insider purchase
• Positive Sentiment: TD Securities recently upgraded Tilray to “strong buy,” contributing to the report that the stock traded higher following an analyst upgrade. The action contrasts with other analysts’ more cautious views and could improve short-term sentiment. Tilray analyst upgrade
• Neutral Sentiment: Tilray has attracted attention as a cannabis-sector and Nasdaq Composite watchlist stock. This may increase visibility, but it does not directly change the company’s earnings or operating outlook. Tilray Nasdaq watchlist article
• Negative Sentiment: Despite reporting record fiscal 2026 revenue, analysts questioned how much of the growth was organic because of Tilray’s reliance on acquisitions. The company also recently reported a substantially wider-than-expected quarterly loss, reinforcing concerns about profitability. Tilray fiscal 2026 results analysis
• Negative Sentiment: Coverage highlighting TLRY’s move into penny-stock territory underscores its high volatility and elevated risk. Although larger cannabis companies could benefit as the legal market consolidates, competition and uncertain profitability remain important risks. Tilray penny-stock coverage

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. TD Securities upgraded Tilray Brands to a “strong-buy” rating in a report on Friday, July 31st. TD Cowen reduced their price objective on Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Weiss Ratings downgraded shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Finally, Wall Street Zen lowered shares of Tilray Brands from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Institutional Trading of Tilray Brands

A number of institutional investors and hedge funds have recently made changes to their positions in TLRY. AQR Capital Management LLC increased its position in Tilray Brands by 1,839.7% in the first quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock worth $399,000 after buying an additional 575,757 shares during the period. XTX Topco Ltd acquired a new stake in shares of Tilray Brands in the 2nd quarter worth about $112,000. Cerity Partners LLC increased its holdings in shares of Tilray Brands by 98.5% in the 2nd quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock worth $38,000 after acquiring an additional 45,929 shares during the period. Ausdal Financial Partners Inc. bought a new stake in Tilray Brands in the 2nd quarter valued at about $939,000. Finally, Bank of America Corp DE lifted its position in Tilray Brands by 26.5% in the 2nd quarter. Bank of America Corp DE now owns 311,810 shares of the company’s stock valued at $129,000 after purchasing an additional 65,379 shares during the last quarter. 9.35% of the stock is currently owned by institutional investors and hedge funds.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.